A detailed history of Bank Of America Corp transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 168,756 shares of LYEL stock, worth $155,255. This represents 0.0% of its overall portfolio holdings.

Number of Shares
168,756
Previous 142,868 18.12%
Holding current value
$155,255
Previous $207,000 12.08%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.13 - $1.88 $29,253 - $48,669
25,888 Added 18.12%
168,756 $232,000
Q2 2024

Aug 14, 2024

SELL
$1.3 - $3.01 $99,596 - $230,605
-76,613 Reduced 34.91%
142,868 $207,000
Q1 2024

May 15, 2024

SELL
$1.71 - $3.07 $2.46 Million - $4.42 Million
-1,441,108 Reduced 86.78%
219,481 $489,000
Q4 2023

Feb 14, 2024

BUY
$1.39 - $2.35 $1.63 Million - $2.75 Million
1,170,361 Added 238.74%
1,660,589 $3.22 Million
Q2 2023

Aug 14, 2023

SELL
$1.89 - $3.86 $469,787 - $959,460
-248,565 Reduced 33.64%
490,228 $1.56 Million
Q1 2023

May 12, 2023

BUY
$1.97 - $3.58 $189,742 - $344,811
96,316 Added 14.99%
738,793 $1.74 Million
Q4 2022

Feb 10, 2023

BUY
$2.78 - $8.09 $1.09 Million - $3.18 Million
392,624 Added 157.14%
642,477 $2.23 Million
Q3 2022

Nov 14, 2022

BUY
$5.54 - $8.27 $530,067 - $791,273
95,680 Added 62.06%
249,853 $1.83 Million
Q2 2022

Aug 12, 2022

SELL
$3.68 - $6.8 $120,203 - $222,115
-32,664 Reduced 17.48%
154,173 $1.01 Million
Q1 2022

May 16, 2022

BUY
$5.05 - $7.7 $503,348 - $767,482
99,673 Added 114.35%
186,837 $943,000
Q4 2021

Feb 08, 2022

BUY
$7.13 - $15.19 $606,984 - $1.29 Million
85,131 Added 4187.46%
87,164 $675,000
Q3 2021

Nov 15, 2021

SELL
$11.0 - $17.95 $686,697 - $1.12 Million
-62,427 Reduced 96.85%
2,033 $30,000
Q2 2021

Sep 13, 2021

BUY
$15.99 - $16.89 $1.03 Million - $1.09 Million
64,460 New
64,460 $1.05 Million

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $228M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.